# GLOW Peptide: The Science of Systemic Tissue Recovery > GLOW peptide combines GHK-Cu, BPC-157, and TB-500 — three research peptides studied for tissue repair, collagen synthesis, and systemic recovery. A literature digest. GHK-Cu, BPC-157, and TB-500 have each generated independent preclinical and clinical evidence for tissue repair, collagen synthesis, and angiogenesis. This site digests that science — organized by constituent, sourced to primary literature, with every quantitative claim cited. ## What Is GLOW Peptide? GLOW peptide is a three-constituent research blend combining GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (body protection compound, 15 amino acids), and TB-500 (the synthetic active heptapeptide of thymosin beta-4). Each constituent has an independent preclinical research profile. No randomized controlled trial has studied the combined formulation as a single compound — all evidence cited on this site pertains to the individual peptides. GHK-Cu is a tripeptide found naturally in human plasma, with levels declining from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 [2]. BPC-157 is a 15-amino-acid stable peptide derived from a partial sequence of human gastric juice protein, studied for tissue-repair and cytoprotective effects across rodent models [8]. TB-500 is the active heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17-23 of full-length thymosin beta-4, responsible for actin sequestration and angiogenic signaling [20]. The GLOW 70 designation refers to a 70 mg total lyophilized peptide formulation distributed across the three constituents in a single vial. For detailed constituent mechanisms, see [GHK-Cu mechanism of action](/research#ghk-cu), [BPC-157 tissue repair](/research#bpc-157), and [TB-500 recovery research](/research#tb-500). ## What Is GLOW Peptide Used For? In preclinical research, the GLOW blend's constituents have been studied for three broad tissue categories: **Extracellular matrix and skin repair.** GHK-Cu stimulated collagen synthesis in cultured human fibroblasts beginning at 10⁻¹² to 10⁻⁹ M — independent of cell proliferation, indicating direct gene-level stimulation [1]. In human clinical trials, 12-week topical application improved skin density, firmness, and wrinkle depth in 41-to-71-participant studies, and procollagen synthesis was achieved in 70% of treated volunteers [23]. **Tendon, ligament, and muscle recovery.** BPC-157 increased growth hormone receptor (GHR) expression up to sevenfold in rat tendon fibroblasts [9] and produced full functional recovery in surgically detached quadriceps muscle in rats by days 21-28 — untreated controls showed permanent disability [10]. TB-500 acts as a chemoattractant for myoblasts at injury sites, driving muscle-fiber regeneration in rodent models [16]. **Angiogenesis and vascular ingrowth.** Both BPC-157 and TB-500 activate VEGFR2-mediated and PI3K/Akt/eNOS signaling cascades to form new capillaries in healing tissue [17]. Thymosin beta-4, the parent protein of TB-500's active fragment, reached Phase II clinical trials for wound repair, corneal healing, and cardiac recovery [17]. The recovery and tissue-repair angle is where the constituent literature is deepest. [GLOW peptide benefits](/benefits) covers the full evidence map by tissue type. ## What Does the GLOW Peptide Do? The GLOW blend targets three complementary mechanisms in sequence. GHK-Cu remodels the extracellular matrix — stimulating collagen I/III and glycosaminoglycan synthesis while suppressing pro-fibrotic TGF-beta1/Smad2/3 signaling [4]. BPC-157 addresses tissue-injury repair by upregulating growth hormone receptor expression in fibroblasts and activating the VEGFR2-Akt-eNOS angiogenic axis [9]. TB-500 drives cell migration and vascular ingrowth via G-actin sequestration and VEGF upregulation in endothelial progenitor cells [15]. Together, the three peptides address what single-constituent protocols typically address individually: matrix-building, injury repair, and vascular recovery. See the [GLOW peptide side effects](/research#side-effects) section on /research for tolerability data across the preclinical literature. ## What Is the GLOW Blend Peptide Stack? The GLOW blend peptide stack is a three-constituent combination designed to address complementary repair pathways in a single formulation. The mechanistic rationale: GHK-Cu provides copper-mediated collagen cross-linking and extracellular matrix organization; BPC-157 provides injury-specific repair via GHR-JAK-STAT signaling in fibroblasts and nitric oxide modulation; TB-500 provides myoblast recruitment and angiogenesis via actin sequestration and VEGF upregulation [17]. Each pairwise combination has its own research rationale. GHK-Cu plus BPC-157 addresses matrix rebuilding and vascular supply simultaneously. BPC-157 plus TB-500 — the most widely referenced pair in the peptide therapy literature — has been noted in a 2026 American Journal of Sports Medicine review study for tissue repair and recovery contexts [finding from common_stacks_research]. The three-peptide stack layers all three mechanisms. No combination trial has been published for the full GLOW blend. The stack rationale is mechanistic extrapolation from individual-constituent evidence. See [GLOW peptide dosage](/dosage) for the studied dose ranges of each constituent. ## GLOW Peptide Ingredients: The Three-Peptide Blend **GHK-Cu** — Glycyl-L-histidyl-L-lysine copper complex. Molecular weight 340.4 Da. A naturally occurring tripeptide complexed with a copper(II) ion; the copper is delivered safely to lysyl oxidase and other copper-dependent enzymes for collagen cross-linking. Plasma levels are endogenous but decline with age [22]. **BPC-157** — Body Protection Compound 157. The sequence GEPPPGKPADDAGLV, 15 amino acids, molecular weight 1419.5 Da. Stable in human gastric juice for over 24 hours; active at microgram-to-nanogram dose ranges in rodent studies [8]. IV half-life 15.2 min in rats, 5.27 min in dogs; IM bioavailability 14-51% across species [14]. **TB-500** — Thymosin beta-4 active fragment, the heptapeptide Ac-LKKTETQ (amino acids 17-23 of the full 43-amino-acid thymosin beta-4 protein). Molecular weight 882.0 Da. Terminal half-life 0.5-2.08 hours IV in Phase I human trial [18]. Detectable in equine plasma at 0.02 ng/mL sensitivity [20]. What Is the GLOW 70 Protocol? The GLOW 70 designation refers to a 70 mg total peptide formulation across the three constituents in a single lyophilized vial. Reconstitution typically uses 3 mL bacteriostatic water, yielding approximately 23 mg/mL total peptide concentration. --- Peer-reviewed findings on recovery, repair, and the three-constituent science behind the GLOW blend — digested here, not sold here.